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Some pharmaceutical products are capable of damaging 
the human auditory system. Technological progress has 
provided numerous resources to monitor hearing but there 
still is some controversy regarding the selection of the most 
sensitive and specific tests. Objective: to analyze audiological 
procedures used in the auditory monitoring of individuals 
exposed to ototoxic medication. Methods: we searched 
the MEDLINE and LILACS literature databases, using terms 
pertinent to audiological monitoring, ototoxicity and cancer. 
The pertaining literature analysis identified two procedures 
often used worldwide for the early detection of auditory 
lesions induced by ototoxic pharmaceutical drugs: high-
frequency audiometry and evoked otoacoustic emissions. 
Both allow early identification of hearing disorders before 
changes are seen in conventional pure-tone audiometry and, 
consequently, before speech understanding is compromised. 
Conclusion: we suggest a hearing monitoring protocol, 
considering the patient’s capability to respond to behavioral 
tests and monitoring timing (first test/follow up). For cancer 
patients, hearing monitoring should be performed in the 
patient’s treatment venue. 
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INTRODUCTION
Hearing loss in adults may cause a number of 
psychosocial changes, because hearing sensitivity deficits 
and the problems related to speech understanding affect 
an individuals’ life style. In children, at the age of speech 
development, the consequences of sensorial deficits, such 
as this one, may be even more disastrous. Since oral lan-
guage development depends much on hearing, a hearing 
impairment is considered severely disabling, for it may 
cause speech development delays, schooling difficulties, 
social and emotional disorders. 
Hearing alterations may be caused by different 
etiologic factors, being them congenital or acquired, and 
it also presents different degrees and types. Among the 
causes of acquired hearing impairment we have the use of 
some ototoxic substance that causes transitory or definitive 
alteration in auditory and vestibular functions1.
Research interest and investment in this field have 
come to provide knowledge on the different types of drugs 
that may cause medication-related ototoxicity. 
Besides medication-related ototoxicity, damage to 
the hearing apparatus may occur from exposure to other 
physical agents such as noise, chemicals and heavy me-
tals such as insecticides, toluene, styrene, ethylbenzene, 
carbon monoxide, carbon disulfide, lead and mercury, 
among others2-4. Notwithstanding, the present study will 
focus on the exposure to medication which are toxic for 
the human ear and the procedures currently available for 
the early diagnosis of hearing alterations caused by such 
exposure. 
In recent years, the influence of chemotherapeutic 
agents over the hearing function, especially cisplatin and 
carboplatin has been studied by some researchers based 
on their action on the hearing system, causing tinnitus and 
hearing sensitivity alterations in some individuals under 
treatment with such drugs.
Thus, the ototoxic potential of such agents is being 
documented5-9, especially among pediatric patients, in 
whom the incidence of bone tumors is greater. In the 
adult population the incidence of head and neck cancer 
is on the rise, and those patients under chemotherapeutic 
treatment may develop hearing impairment10.
When discussing the pediatric population, not only 
cancer treatment is important, but it is also of the uttermost 
importance to consider the social aspects related to the 
disease, since the child is inserted in a family and school 
context. Cure should be based not only on the biological 
recovery, but also in the well being and the patient’s qua-
lity of life. In these regards, from the very beginning of 
treatment, the patient should not be deprived of hearing 
monitoring. 
This discussion on the need to establish a hearing 
assessment protocol for the population of patients ex-
posed to ototoxic agents is nothing new. Back in 1984, 
Fausti et al.11 already pointed this need out, and based 
on the selection of some studies on the early detection 
of ototoxicity caused by antineoplastic agents, they con-
cluded that their effect on hearing was well documented, 
however there was still no consensus among researchers 
on which of the methods would be the one most suitable 
for hearing monitoring. 
Hearing monitoring should allow for the lesion to 
be identified before there is damage to the tonal thresholds 
on conventional frequencies and, consequently, impair the 
individual’s speech recognition. Thus, we understand that 
to monitor an individual under treatment by an ototoxic 
agent means to try, whenever possible, to preserve his/her 
hearing, or to detect early on a hearing loss and minimize 
its consequences to the individual’s life by means of proper 
medical and hearing treatments.
Monitoring should be carried out since it provides 
early evidences of dose limits for hearing loss, thus allo-
wing for preventing or mitigating ototoxicity severity, and 
when hearing loss is certain, there is the possibility of early 
hearing rehabilitation through the fitting of an individual 
hearing amplification device. 
In this process, besides needing an otolaryngologist 
and a speech and hearing therapist in the multidisciplinary 
team, often times the psychologist is crucial, especially 
when the individual at stake is a teenager, struggling to 
accept the need for a hearing aid, or even to provide 
emotional support for the family that is frail at times of 
severe illnesses such as cancer, and also needs to come 
to terms with hearing loss. 
Despite all procedures and equipment available 
for the hearing monitoring of individuals exposed to po-
tentially ototoxic drugs, in most centers this population is 
seen without an effective program implemented to assess 
hearing, and interfere early on in cases when there already 
is hearing loss installed. 
Analyzing the existing literature in these regards we 
see two procedures that have been used at a worldwide 
level for the early detection of ototoxic drug-induced 
hearing loss: high frequency audiometry and evoked 
otoacoustic emissions, notwithstanding, despite the avai-
lability of international assessment protocols, we still need 
to discuss the clinical application of such procedures as 
far as hearing monitoring is concerned. 
Having said that, the goal of our present study was 
to survey the literature, check and analyze the audiolo-
gical procedures used in the hearing monitoring of those 
individuals exposed to ototoxic medication. We surveyed 
the MEDLINE and LILACS medical databases, based on 
using the keywords for the following themes: hearing 
monitoring, ototoxicity and cancer. We also surveyed 
other electronic sites related to audiology such as the 
American Speech-Language-Hearing Association (ASHA), 
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American Academy of Otolaryngology - Head and Neck 
Surgery (AAO-HNS), American Academy of Audiology, 
International Society of Audiology, Brazilian Society of 
Pediatrics, Brazilian Association of Otorhinolaryngolo-
gy/Neck and Facial Surgery, Brazilian Society of Speech 
and Hearing Therapy, and the Brazilian Association of 
Otorhino-pediatrics. 
As a result of this electronic search we found about 
1,400 papers. The criteria used to select the studies were: 
publication between January of 1980 and July of 2005; cli-
nical assays with adults or children, stressing the protocols 
used for auditory monitoring. 
 LITERATURE REVIEW
Aguiar12 carried out a study with a number of drugs 
that may affect the auditory and vestibular systems either 
centrally or peripherally, and developed a summary of 
all the results published by some researchers, shown on 
Table 1. 
In 1997 Moussalle et al.13 highlighted the fact that 
drug-induced ototoxicity should attract multidisciplinary 
medical interest, since the use of such drugs may involve 
liver and kidneys, and they are prescribed by all medical 
specialties, often times inadequately and as a first choice 
treatment, having its ototoxic potential totally disregarded 
and sometimes not believed. 
Having in mind the hearing alterations caused to 
those patients who use ototoxic agents, it becomes para-
mount to monitor their hearing, thus allowing for an early 
diagnosis and identification of the lesion progression. 
Within these lines, after detecting the alterations caused 
to the patient’s hearing health, actions such as the use of 
alternative treatment modalities, dose reduction or drug 
change, or even keeping the status quo but preparing the 
family for an eventual hearing loss, may be taken by the 
specialist14,15.
It is agreed upon among researchers in this field 
that hearing alterations caused by the use of ototoxic drugs 
starts on the basal cochlea, affecting high frequencies, and 
it may evolve towards the cochlear apex and later affect 
low and middle range frequencies, thus impacting all spe-
ech frequencies16-22, however, there are some controversies 
regarding the action mechanisms of these agents and their 
effect on hearing16,19,21,22.
Because of variables such as type of agent; dose 
duration; serum level and drug build up effect;  renal di-
sorders; individual susceptibility; hearing monitoring onset 
after treatment onset; among others; there are some aspects 
that require investigation. Among the latter we may think 
of the very hearing loss reversibility; affected areas of the 
hearing apparatus; the alteration rate of progression and 
the procedure able to detect any auditory lesion as early 
as possible.
According to reports from researchers that approach 
such themes, the hearing tests to be carried out during 
monitoring include conventional and high frequency au-
diometry, speech recognition tests, acoustic immittance 
measures and, for children, evoked otoacoustic emissions, 
Brain Stem Evoked Response Audiometry (BERA), and 
Electrocochleography (ECOGh)6,18,19,23,24.
In 1994 a committee made up of members of the 
American Speech-Language-Hearing Association (ASHA)25 
presented some guidelines for hearing monitoring of 
individuals who are undergoing the use of cochleotoxic 
medication. According to this committee, it is important 
that the first audiological evaluation be carried out before 
drug therapy onset. When this is not possible and depen-
ding on the drug used, this assessment should happen no 
later than 24 hours of the first dose administration (in the 
case of chemotherapeutic agents such as cisplatin), and 
within the first 72 hours when the treatment is carried out 
with antibiotics such as aminoglicosides. The monitoring 
program should be set up according to the type of ototoxic 
medication being used. In order to early detect ototoxi-
city, patients being treated with antibiotic agents should 
be weekly assessed; and in extreme cases, every 2 or 3 
days. Those patients being treated with platin analogues 
(cisplatin and carboplatin) should undergo audiological 
evaluations within 24 hours of chemotherapy onset.  
Thus, ASHA25 recommended a protocol that first 
stresses the medical interview, followed by otoscopy 
and, later, the hearing assessment made up of a threshold 
tonal audiometry and a high frequency audiometry, lo-
goaudiometry and acoustic immittance measures. Such 
association suggests that both logoaudiometry and acoustic 
immittance measure should be carried out as soon as the 
first evaluation is performed, but they do not have to be 
done again in the successive evaluations, unless there are 
threshold changes.  Moreover, they suggest that EOE and 
BERA should be carried out when the patient is unable 
to respond to subjective testing. 
Some studies show that the BERA is efficacious in 
the early detection of cisplatin-induced hearing loss, by 
following Wave V as a minimum hearing level26-28.
High frequency audiometry is being mentioned 
in the international literature as a sensitive procedure 
in the early detection of hearing alterations caused by 
ototoxic medication, and many investigators have stated 
that hearing monitoring is fundamental in order to avoid 
degenerative processes occurring to the cochlea spiral 
process7,11,13,16,17,20,25,28-33, although there is still no consen-
sus as to the criteria used for results interpretation. Park20 
recommends the use high frequency audiometry, followed 
by pure tone audiometry and the investigation of acoustic 
reflexes, in this order.  In order to record high frequency 
thresholds, the patient’s participation is paramount in order 
to achieve a reliable result, having in mind that this is a 
behavioral and subjective evaluation34.
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Table 1. Results summary from some studies classified according to drug type and ototoxic effect. 
TOXIC EFFECTS
 AUTHOR / YEAR DRUG COCLEO TOXIC VESTIBULOTOXIC NEURO TOXIC
Aminoglicoside anti-
biotics
Schacht (1993) Streptomycin + + -
Schacht (1993) Diistreptomycin + + -
Matz, Rohn Meyerhoff e Wri-
ght (1993)
Neomycin + - -
Webster et al. (1970); Matz 
(1993)
Gentamycin + - -
Matz (1993) Amikacin + - -
Matz (1993) Kanamycin + - -
Other antibiotics
Stupp (1973); Oliveira (1986); 
Brummett (1993)
Erythromycin + - -
Brummett (1993) Vancomycin + + -
Kahonen e Tarkkanen (1969); 
Rohn, Meyerhoff e Wright 
(1993)
Polymyxin B + - -
Patterson e Gulik (1969); 
Rohn, Meyerhoff e Wright 
(1993)
Chloramphenicol + - -
Oliveira (1986) Ampicillin - + -
Oliveira (1986) Minocycline - + -
Oliveira (1986) Capreomycin + + -
Oliveira (1986) Colistin + - -
Topical Agents
Morionza e Sikora (1981) Antiseptic (alcohol) + - -
Parker e James (1978)
Antifungal (Ggriseo-
fulvin)
+ - -
Insel (1990); Jung et al. 
(1993)
Salicylate + - -
Insel (1990)
Non-steroidal anti-in-
flammatory
+ - -
Jung et al.(1993) Quinine + + -
Loop diuretics
Gerger (1988); Hass (1989) Ethacrynic acid + - -
Boston Collaborative Drug 
Sevillance Program (1973)
Furosemide + + -
Chemotherapeutic 
agents
 
Carenza Vellani e Kinngston 
(1986); Otto (1988); Schweit-
zer (1993)
Cisplatin + + +
Schucknecht (1979); Schweit-
zer (1993)
Nitrogenated Mus-
tard 
+ - -
Schweitzer (1993);
6-amino nicotinamide
(6-NA) + - +
Serafy (1981)  Vincristine sulphate + - +
Schweitzer (1993); Misonidazole + - -
Legend: (+) ototoxic effect present; (-) ototoxic effect absent
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Fausti et al.17 proposed a testing procedure in five 
frequencies (8kHz, 9kHz, 10kHz, 12.5kHz and 16kHz) 
as an alternative monitoring protocol for those patients 
exposed to cisplatin, since they may not be capable of 
responding or even tolerating such an intense array of 
audiological tests. 
As we analyze the specific literature on the use of 
EOE in the auditory monitoring for ototoxic-drug-exposed 
patients, we see that it evaluates the cochlear bioactive 
mechanism corresponding to the external hair cell res-
ponses within the cochlea. According to Kemp35 & Probst 
et al.36, transient stimulus evoked otoacoustic emissions 
(TEEOE) are almost always present in individuals who 
have audiometric thresholds higher than 30 dBHL. Ho-
wever, investigators such as Desai et al.37 and Prasher & 
Sulkowski38 stated that, when there is an initial involvement 
of the external hair cells, the TEEOE may be absent, even 
under normal hearing thresholds. 
Because of this very property, this procedure has 
been used in hearing monitoring in order to check co-
chlear alterations caused by ototoxic drugs, by means of 
reducing the amplitude of emissions before alterations 
happen to the tonal thresholds8,9,21,22,39-46. Moreover, this 
is an objective analysis (and not behavioral), that may be 
carried out even when the child is asleep.
Paz et al.47 concluded in their studies that 100 mg/
m2 of cisplatin caused a reduction in the transient stimu-
lus evoked otoacoustic emissions and in the distortion 
product evoked otoacoustic emissions (DPEOAE), more 
prominently in the high frequencies and directly related 
to dose build up. They also stated that this reduction in 
emission amplitudes happens even before tinnitus and 
subjective hearing loss onset, saying that both TEEOE and 
DPEOAE are useful methods for the early detection of 
cisplatin-induced hearing loss and that they complement 
each other. 
Within this context, DPEOAE is more sensitive in 
the early detection of hearing alterations when compared 
to TEEOE, since it assess a broader frequency range, in-
cluding higher frequencies, which are the ones normally 
affected by ototoxic medication14.
Jacob et al.48 researched on the EOAE and high 
frequency audiometry in 44 cancer patients with ages 
ranging between 3 and 28 years who were being treated 
by chemotherapy. The results of both tests were then com-
pared to those from the control group (without hearing 
complaints or exposed to risk factors), and they noticed 
that high frequency audiometry was more sensitive in the 
early detection of hearing alterations. Notwithstanding, the 
same authors highlighted that the choice of procedure to 
be used in auditory monitoring, in other words, the op-
tion of carrying out auditory monitoring by means of high 
frequency audiometry or evoked otoacoustic emissions 
depends on two factors: (1) the specific characteristics 
of the individual being treated, such as: age, capacity to 
answer behavioral tests, and the patient’s clinical status 
(general health); (2) the goals of the team responsible for 
the patient that intends to undergo hearing monitoring. 
After pondering on these two factors, the authors recom-
mend the inclusion of EOAE in the hearing assessment 
protocol.  
DISCUSSION
There is no doubt that hearing monitoring in indivi-
duals exposed to ototoxic medication, by means of highly 
sensitive and specific procedures, is crucial in order to 
identify hearing alterations before those more significant 
frequencies for speech intelligibility are affected. This 
statement is even more pertaining for the pediatric po-
pulation undergoing treatment with potentially ototoxic 
medication, since hearing may seriously compromise their 
speech acquisition and development and, consequently, 
bring about difficulties in their psychosocial and learning 
development. 
Physicians increasingly want to know more about 
drugs that may damage the human hearing apparatus, in 
an attempt to preserve a patient’s hearing function, and 
thus, such ototoxic drugs are increasingly less present in 
the therapeutic arsenal. 
However, in many situations the use of such drug 
is unavoidable, as is the case of cancer patients under 
chemotherapy. In such cases, preserving the patient’s life 
is the ultimate therapeutic goal. Notwithstanding, since the 
knowledge on different types of chemotherapeutic agents 
and other ototoxic drugs has been increasing, early diagno-
sis and, consequently, the cure of cancer are increasingly 
more present in oncology wards, especially in pediatric 
oncology. Therefore, cancer treatment success must be 
associated to a concern with the patient’s well being and 
his/her quality of life, including hearing care. 
Thus, auditory assessment is essential for those 
individuals exposed to high doses of chemotherapeutic 
agents, for ototoxicity identification and rehabilitation 
purposes. Hearing tests should be carried out before and 
after the onset of ototoxic medication deployment, so that 
the patient may be properly followed up. 
We should also stress the importance of always 
asking both the patient and his/her family about the recent 
use of ototoxic drugs, family or personal history of hearing 
impairment, and pay close attention to the use of another 
concurrent ototoxic drug. Such information is very useful 
in order to survey risk indicators for hearing loss, since 
the synergy of different ototoxic agents may enhance their 
effect on hearing. Moreover, the use of different ototoxic 
agents is commonly done in chemotherapy. 
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Our survey and reading of the national research on 
this theme lead us to make some analysis. Publications in 
this field are scarce, and the existing ones are restricted 
to pointing out the deleterious consequences of ototoxic 
drugs on hearing, but do not present evidences on the 
thresholds of ototoxic drug use in order to prevent or 
mitigate the ototoxicity severity6,7,10,13,18,19,23,33,45,48,49.
Such statement elicits some considerations. First it 
highlights the difference in the multidisciplinary care gi-
ven to individuals under chemotherapeutic care in Brazil 
when compared to places like the United States and some 
European countries. 
Our settings are somewhat different from that of the-
se countries, for they count on financial investment for the 
development of research in this field. Thus, the difficulties 
in obtaining research grants for studies in the most diverse 
health fields do restrict the necessary magnitude of these 
types of scientific investigations. In such a context, we 
discuss some aspects that are paramount for the hearing 
monitoring procedures used by large centers abroad and 
also in the care of individuals exposed to chemotherapeutic 
agents or other types of ototoxic drugs. 
First, we list the easy access these individuals have 
towards hearing assessments which are carried out within 
the person’s treatment venue (ideally) or even in the ease 
of transportation towards specialized centers where these 
assessments are carried out. In Brazil, it is not routine in 
most of the large centers that treat individuals with poten-
tially ototoxic medication, such as the oncology wards, to 
offer effective auditory monitoring for those patients that 
start on cancer treatment. As a major difficulty towards 
performing such monitoring we stress the lack of an au-
diology department that makes the equipment for such 
evaluation available. Moreover, there still is an important 
underreferral of these patients to the otorhinolaryngologist 
for proper audiologic assessment. 
Another very relevant aspect is a precise medication 
control and their proper dosing, among other factors, by 
the results attained in audiological tests, seeking efficient 
alternatives for the treatment of cancer or other diseases 
aiming at hearing preservation. In this direction, hearing 
monitoring is fundamental, and bearing in mind the 
individual’s susceptibility for hearing loss, the physician 
should not be stuck only to medication dosage in order to 
predict whether or not there is a risk for ototoxicity25.
Specialized literature provides hearing assessent 
protocols for this population, however, we still lack a con-
sensus among researchers on which should be the most 
adequate protocol to be used in hearing monitoring. 
Thus, it is necessary to make a few comments regar-
ding each procedure used in the hearing monitoring of in-
dividuals who are being treated by ototoxic medication. 
Threshold tonal audiometry comes up as one of 
the procedures used for this end6,7,13,18,20,23,25, however, it is 
important to clarify that it should be carried out aiming at 
investigating the patient’s hearing acuity before treatment 
onset, since this procedure is not very sensitive for the 
early detection of hearing alterations.
High frequency audiometry has been considered 
the method of choice by some investigations, because it 
allows for hearing alterations detection before the most sig-
nificant frequencies for communication are affected7,11,13,16-
18,20,28-33,49.
When we think that the drug-induced hearing 
alterations happen in the basal turn of the cochlea, first 
affecting the high frequencies16-22, and the many papers that 
mention this procedure as efficient for the early detection 
of ototoxicity, high frequency audiometry should be part 
of the hearing monitoring protocol. Notwithstanding, it is 
important to clear up that since it is a behavioral method 
used to assess hearing, and depending on the child’s age, 
neurological status or the patient’s general health status, 
such procedure may not be possible. 
Under such assumptions, it is recommended to 
include otoacoustic emissions in the assessment protocol 
when the patient is unable to respond to the behavioral 
tests, having seen that many papers confirm its clinical 
application on the early detection of ototoxicity8,9,14,21,22,39-
48,50. It is worth stressing that, as aforementioned, since the 
frequency range assessed in TEEOE is carried out between 
1 and 4kHz, DPEOAE should not be excluded, because 
TEEOE may be present even when there are alterations 
in the outer hair cells in the most basal portion of the 
spiral organ (base membrane vibration for those sounds 
in frequencies above 4kHz)48. In these cases, considering 
that the DPEOAE investigate the cochlear amplification 
mechanism at a higher frequency range, such alterations 
may be detected from the reduction in response amplitude 
or its absence in the higher frequencies. 
As one includes EOAE in the evaluation protocol, 
it is paramount to perform immittance measures during 
the same assessment session, so that the investigator 
may safely interpret if a drop in EOAE amplitude or its 
absence happened because of a defect on the amplifying 
mechanism of the outer hair cells or because of some 
middle ear transmission mechanism alteration. Immittance 
measures may be also used to detect the presence of the 
stapedial reflex, offering the possibility of confirming the 
presence of a Metz recruitment, since ototoxicity causes 
cochlear lesion. 
When one performs hearing monitoring by means 
of high frequencies audiometry, or using otoacoustic 
emissions, one must necessarily have an assessment made 
prior to medication onset, since responses may vary within 
normality. Moreover, the results of both evaluations are 
influenced by age, by prior hearing impairment in the 
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high frequencies, and there may also be EOAE amplitude 
reduction, non-medication related. 
At last, considering the pediatric population, another 
method to assess hearing, but limited for the early detec-
tion of ototoxicity, is the Brain Stem Evoked Response 
Audiometry (BERA). Although much used in the clinical 
routine for obtaining the electrophysiological threshold, it 
does not assess responses in the high frequencies (above 
4 kHz) where the cochlea is affected by ototoxic drug 
exposure. Notwithstanding, such procedure may and 
should be used to monitor those individuals exposed to 
neurotoxic agents. 
The hearing monitoring protocol must be structured 
according to the particular characteristics of each individual 
patient, such as age, capability to respond to the tests, 
clinical status, and others. Thus, as procedures for hearing 
evaluation and monitoring we suggest:
 
1. For individuals who do not respond to behavioral 
hearing evaluation:
1.1 - on the first assessment and on the subsequent 
ones:
- Transient stimulus and distortion product evoked 
otoacoustic emissions recording;
- Acoustic immittance measures (tympanometry and 
contra and ipsilateral acoustic reflex thresholds);
- Brain Stem Evoked Response Audiometry, inclu-
ding electrophysiological threshold testing.
 
In some cases, the child may present inconsistent 
responses in the pure tone threshold recording, but provi-
de consistent answers on the speech recognition threshold 
or speech detectability by means of figures or simple 
verbal commands. This information is deemed extremely 
useful in order to assess a child’s hearing when he/she 
has been submitted only to EOAE. If there is reduction in 
these thresholds in subsequent evaluations, coupled with 
amplitude reduction in EOAE responses, hearing sensiti-
vity deterioration becomes more evident and should be 
considered. 
 
2. For both children and adults responders to beha-
vioral hearing assessment:
2.1 - On the first assessment:
- Threshold tonal audiometry and logoaudiome-
try;
- Acoustic immittance measures (tympanometry 
and acoustic reflex threshold acquisition contra and ip-
silateral);
- High frequency audiometry in 4 frequency ran-
ges;
- DPEOAE and TEEOE;
- Brain Stem Evoked Response Audiometry when 
the medication used is potentially neurotoxic.
 
2.2 - On subsequent assessments:
- High frequency audiometry in four frequency 
ranges;
- Brain Stem Evoked Response Audiometry when 
the medication used is potentially neurotoxic.
 
Threshold tonal audiometry and the EOAE recor-
dings may be carried out on subsequent assessments if 
there is any worsening in the high frequencies audiometry 
results (worsening in the threshold equal to or greater 
than 15 dB in at least two frequencies evaluated between 
500 and 4000Hz), the acoustic reflex testing should be 
carried out in order to investigate recruitment. At this 
moment, audiometry is paramount, since by means of its 
results, the team of caregivers will decide on the fitting 
of a hearing aid. 
 FINAL REMARKS
Technological progress has made available nume-
rous resources that can be used for hearing monitoring 
purposes. Thus, early detection of hearing loss by means of 
hearing assessment procedures with high sensitivity in the 
identification of hearing drug-induced hearing alterations 
is crucial. Moreover, when hearing impairment installs, a 
hearing monitoring program may provide the individual 
with the early option for selection, indication and fitting 
of an individual hearing amplification device (IHAD), as 
well as hearing rehabilitation. 
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